Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for SPRY

Stock Name	Silverback Therapeutics Inc
Ticker	SPRY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US82835W1080

Show aggregate SPRY holdings

News associated with SPRY

XTX Topco Ltd Grows Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): XTX Topco Ltd grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 54.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,647 shares of the company’s stock after buying an additional 17,429 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-08-06 05:18:53
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus PT from Brokerages: Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year […] - 2025-07-14 02:56:47
Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Oppenheimer & Co. Inc. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 1st quarter, Holdings Channel reports. The firm purchased 15,014 shares of the company’s stock, valued at approximately $189,000. Other large investors have also modified their holdings of the company. Wellington Management Group LLP boosted its position in […] - 2025-07-04 04:36:46
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of Stock: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) major shareholder James E. Flynn sold 740,149 shares of the business’s stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the transaction, the insider directly owned 4,887,254 shares […] - 2025-07-03 05:26:53
ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to “Hold” at Wall Street Zen: Wall Street Zen upgraded shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. A number of other brokerages have also recently commented on SPRY. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set […] - 2025-06-29 05:18:51
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target […] - 2025-06-19 02:46:58
Wellington Management Group LLP Buys 917 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Wellington Management Group LLP raised its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 163,252 shares of the company’s stock after purchasing an additional 917 shares during the period. Wellington Management Group LLP’s holdings in ARS Pharmaceuticals were worth $1,722,000 as of […] - 2025-06-06 06:12:51
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by Deutsche Bank AG: Deutsche Bank AG increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 50.8% in the fourth quarter, Holdings Channel reports. The firm owned 43,377 shares of the company’s stock after purchasing an additional 14,604 shares during the period. Deutsche Bank AG’s holdings in ARS Pharmaceuticals were worth $458,000 as of its most […] - 2025-05-30 04:46:50
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp: Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of […] - 2025-05-22 04:20:52
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Position Boosted by Wells Fargo & Company MN: Wells Fargo & Company MN lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,701 shares of the company’s stock after acquiring an additional 13,361 shares during the quarter. Wells Fargo & Company MN’s holdings in ARS Pharmaceuticals were worth $440,000 […] - 2025-05-05 05:00:50
Brokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month […] - 2025-04-30 02:10:55
Raymond James Financial Inc. Takes $6.58 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Raymond James Financial Inc. purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other institutional investors have also made […] - 2025-04-24 06:31:08
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,002 Shares: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total transaction of $615,024.60. Following the sale, the director now owns 210,346 shares of the company’s […] - 2025-04-10 05:12:56
Intech Investment Management LLC Has $322,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Intech Investment Management LLC lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 85.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,545 shares of the company’s stock after buying an additional 14,051 shares during the quarter. Intech Investment […] - 2025-03-26 07:16:48
Raymond James Financial Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Raymond James Financial Inc. purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 623,281 shares of the company’s stock, valued at approximately $6,576,000. Other large investors also recently added to or reduced their stakes in the company. Compass Capital Corp MA ADV purchased […] - 2025-03-24 05:50:52
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY): Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, MarketBeat.com reports. The firm issued a sector outperform rating and a $30.00 target price on the stock. SPRY has been the subject of several other research reports. Raymond James lifted their target price on ARS Pharmaceuticals from […] - 2025-03-10 03:50:50
Allspring Global Investments Holdings LLC Buys 165,950 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Allspring Global Investments Holdings LLC increased its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 93.1% during the 4th quarter, Holdings Channel reports. The fund owned 344,171 shares of the company’s stock after acquiring an additional 165,950 shares during the period. Allspring Global Investments Holdings LLC’s holdings in ARS Pharmaceuticals were […] - 2025-02-21 06:12:48

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) SPRY holdings

Date	Number of SPRY Shares Held	Base Market Value of SPRY Shares	Local Market Value of SPRY Shares	Change in SPRY Shares Held	Change in SPRY Base Value	Current Price per SPRY Share Held	Previous Price per SPRY Share Held
2025-12-24 (Wednesday)	65,762	USD 754,948	USD 754,948	0	USD 29,593	USD 11.48	USD 11.03
2025-12-23 (Tuesday)	65,762	USD 725,355	USD 725,355	-1,860	USD -42,831	USD 11.03	USD 11.36
2025-12-22 (Monday)	67,622	USD 768,186	USD 768,186	0	USD 58,831	USD 11.36	USD 10.49
2025-12-19 (Friday)	67,622	USD 709,355	USD 709,355	-7,669	USD -30,003	USD 10.49	USD 9.82001
2025-12-18 (Thursday)	75,291	USD 739,358	USD 739,358	0	USD -18,822	USD 9.82001	USD 10.07
2025-12-17 (Wednesday)	75,291	USD 758,180	USD 758,180	-870	USD -53,696	USD 10.07	USD 10.66
2025-12-16 (Tuesday)	76,161	USD 811,876	USD 811,876	-174	USD 3,488	USD 10.66	USD 10.59
2025-12-15 (Monday)	76,335	USD 808,388	USD 808,388	348	USD 30,281	USD 10.59	USD 10.24
2025-12-12 (Friday)	75,987	USD 778,107	USD 778,107	0	USD -74,467	USD 10.24	USD 11.22
2025-12-11 (Thursday)	75,987	USD 852,574	USD 852,574	4,703	USD 108,369	USD 11.22	USD 10.44
2025-12-10 (Wednesday)	71,284	USD 744,205	USD 744,205	0	USD 36,355	USD 10.44	USD 9.93

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SPRY by Blackrock for IE00BDZVHG35

Show aggregate share trades of SPRY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-23 SELL -1,860 11.320 10.770 10.825 USD -20,135 12.74 Profit of 3,561 on sale
2025-12-19 SELL -7,669 10.990 9.800 9.919 USD -76,069 12.76 Profit of 21,761 on sale
2025-12-17 SELL -870 10.700 10.000 10.070 USD -8,761 12.78 Profit of 2,360 on sale
2025-12-16 SELL -174 10.685 10.390 10.420 USD -1,813 12.79 Profit of 413 on sale
2025-12-15 BUY 348 10.712 10.020 10.089 USD 3,511 12.80
2025-12-11 BUY 4,703 11.450 10.400 10.505 USD 49,405 12.82
2025-12-04 BUY 3,260 10.020 9.440 9.498 USD 30,963 12.89
2025-12-02 BUY 2,460 9.600 9.020 9.078 USD 22,332 12.93
2025-11-28 BUY 164 9.690 9.329 9.365 USD 1,536 12.96
2025-11-26 BUY 492 9.760 9.250 9.301 USD 4,576 13.00
2025-11-25 BUY 820 9.325 7.970 8.105 USD 6,647 13.01
2025-11-24 BUY 165 8.090 7.560 7.613 USD 1,256 13.04
2025-11-20 SELL -652 7.397 6.730 6.797 USD -4,431 13.10 Profit of 4,110 on sale
2025-11-19 BUY 163 7.400 6.935 6.981 USD 1,138 13.13
2025-11-18 BUY 978 7.360 6.950 6.991 USD 6,837 13.16
2025-11-17 BUY 326 8.160 7.290 7.377 USD 2,405 13.19
2025-11-14 BUY 163 8.665 8.190 8.237 USD 1,343 13.22
2025-11-12 BUY 163 9.070 8.600 8.647 USD 1,409 13.27
2025-11-10 BUY 162 10.307 8.420 8.609 USD 1,395 13.32
2025-11-06 BUY 162 9.000 8.140 8.226 USD 1,333 13.37
2025-11-04 BUY 163 8.780 8.330 8.375 USD 1,365 13.42
2025-10-30 BUY 815 9.000 8.590 8.631 USD 7,034 13.50
2025-10-29 BUY 326 8.980 9.460 9.412 USD 3,068 13.52
2025-10-22 SELL -648 9.720 9.940 9.918 USD -6,427 13.64 Profit of 2,410 on sale
2025-10-20 BUY 324 10.010 10.375 10.339 USD 3,350 13.68
2025-10-17 BUY 809 10.050 10.170 10.158 USD 8,218 13.70
2025-10-15 BUY 1,288 10.970 11.060 11.051 USD 14,234 13.72
2025-10-03 BUY 1,141 10.310 11.030 10.958 USD 12,503 13.76
2025-10-02 BUY 163 10.280 10.500 10.478 USD 1,708 13.78
2025-09-30 BUY 326 10.050 10.400 10.365 USD 3,379 13.82
2025-09-26 BUY 326 9.800 9.925 9.913 USD 3,231 13.87
2025-09-25 BUY 326 9.540 9.700 9.684 USD 3,157 13.90
2025-09-18 BUY 173 9.930 9.980 9.975 USD 1,726 13.93
2025-09-17 BUY 519 9.570 9.800 9.777 USD 5,074 13.95
2025-07-17 SELL -340 18.350 18.440 18.431 USD -6,267 13.90 Loss of -1,540 on sale
2025-07-16 BUY 1,584 17.870 17.990 17.978 USD 28,477 13.88
2025-07-11 SELL -1,328 17.690 18.045 18.010 USD -23,917 13.80 Loss of -5,589 on sale
2025-07-02 BUY 9,130 16.750 16.760 16.759 USD 153,010 13.71
2025-06-25 BUY 332 17.260 17.540 17.512 USD 5,814 13.59
2025-06-11 BUY 334 14.340 14.800 14.754 USD 4,928 13.45
2025-06-10 BUY 334 14.690 14.780 14.771 USD 4,934 13.44
2025-06-04 SELL -167 13.820 14.700 14.612 USD -2,440 13.42 Loss of -199 on sale
2025-04-23 BUY 166 14.380 15.440 15.334 USD 2,545 13.22
2025-04-10 SELL -1,328 13.240 13.663 13.621 USD -18,088 13.09 Loss of -710 on sale
2025-04-08 SELL -166 12.330 13.420 13.311 USD -2,210 13.09 Loss of -36 on sale
2025-04-07 SELL -166 12.830 13.785 13.689 USD -2,272 13.10 Loss of -99 on sale
2025-04-04 SELL -835 12.800 13.730 13.637 USD -11,387 13.10 Loss of -450 on sale
2025-04-01 BUY 2,480 12.530 12.850 12.818 USD 31,789 13.11
2025-03-31 SELL -483 12.580 12.770 12.751 USD -6,159 13.11 Profit of 175 on sale
2025-03-21 BUY 2,109 12.360 14.250 14.061 USD 29,655 13.15
2025-03-14 SELL -2,480 11.870 12.255 12.217 USD -30,297 13.22 Profit of 2,478 on sale
2025-03-07 SELL -310 10.850 11.160 11.129 USD -3,450 13.35 Profit of 687 on sale
2025-03-04 SELL -155 10.510 10.720 10.699 USD -1,658 13.47 Profit of 430 on sale
2025-02-25 BUY 310 10.560 10.980 10.938 USD 3,391 13.74
2025-02-19 SELL -154 12.000 12.020 12.018 USD -1,851 13.91 Profit of 291 on sale
2025-02-13 BUY 462 11.920 12.010 12.001 USD 5,544 14.07
2025-02-12 BUY 154 11.630 11.770 11.756 USD 1,810 14.12
2025-02-11 BUY 616 11.550 12.030 11.982 USD 7,381 14.17
2024-12-30 SELL -4,737 10.620 10.690 10.683 USD -50,605 14.73 Profit of 19,151 on sale
2024-11-18 SELL -2,490 13.780 14.370 14.311 USD -35,634 15.64 Profit of 3,298 on sale
2024-11-08 SELL -166 17.040 17.070 17.067 USD -2,833 15.47 Loss of -266 on sale
2024-10-21 SELL -166 16.720 16.750 16.747 USD -2,780 0.00 Loss of -2,780 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-23	SELL	-1,860	11.320	10.770	10.825	USD -20,135	12.74 Profit of 3,561 on sale
2025-12-19	SELL	-7,669	10.990	9.800	9.919	USD -76,069	12.76 Profit of 21,761 on sale
2025-12-17	SELL	-870	10.700	10.000	10.070	USD -8,761	12.78 Profit of 2,360 on sale
2025-12-16	SELL	-174	10.685	10.390	10.420	USD -1,813	12.79 Profit of 413 on sale
2025-12-15	BUY	348	10.712	10.020	10.089	USD 3,511	12.80
2025-12-11	BUY	4,703	11.450	10.400	10.505	USD 49,405	12.82
2025-12-04	BUY	3,260	10.020	9.440	9.498	USD 30,963	12.89
2025-12-02	BUY	2,460	9.600	9.020	9.078	USD 22,332	12.93
2025-11-28	BUY	164	9.690	9.329	9.365	USD 1,536	12.96
2025-11-26	BUY	492	9.760	9.250	9.301	USD 4,576	13.00
2025-11-25	BUY	820	9.325	7.970	8.105	USD 6,647	13.01
2025-11-24	BUY	165	8.090	7.560	7.613	USD 1,256	13.04
2025-11-20	SELL	-652	7.397	6.730	6.797	USD -4,431	13.10 Profit of 4,110 on sale
2025-11-19	BUY	163	7.400	6.935	6.981	USD 1,138	13.13
2025-11-18	BUY	978	7.360	6.950	6.991	USD 6,837	13.16
2025-11-17	BUY	326	8.160	7.290	7.377	USD 2,405	13.19
2025-11-14	BUY	163	8.665	8.190	8.237	USD 1,343	13.22
2025-11-12	BUY	163	9.070	8.600	8.647	USD 1,409	13.27
2025-11-10	BUY	162	10.307	8.420	8.609	USD 1,395	13.32
2025-11-06	BUY	162	9.000	8.140	8.226	USD 1,333	13.37
2025-11-04	BUY	163	8.780	8.330	8.375	USD 1,365	13.42
2025-10-30	BUY	815	9.000	8.590	8.631	USD 7,034	13.50
2025-10-29	BUY	326	8.980	9.460	9.412	USD 3,068	13.52
2025-10-22	SELL	-648	9.720	9.940	9.918	USD -6,427	13.64 Profit of 2,410 on sale
2025-10-20	BUY	324	10.010	10.375	10.339	USD 3,350	13.68
2025-10-17	BUY	809	10.050	10.170	10.158	USD 8,218	13.70
2025-10-15	BUY	1,288	10.970	11.060	11.051	USD 14,234	13.72
2025-10-03	BUY	1,141	10.310	11.030	10.958	USD 12,503	13.76
2025-10-02	BUY	163	10.280	10.500	10.478	USD 1,708	13.78
2025-09-30	BUY	326	10.050	10.400	10.365	USD 3,379	13.82
2025-09-26	BUY	326	9.800	9.925	9.913	USD 3,231	13.87
2025-09-25	BUY	326	9.540	9.700	9.684	USD 3,157	13.90
2025-09-18	BUY	173	9.930	9.980	9.975	USD 1,726	13.93
2025-09-17	BUY	519	9.570	9.800	9.777	USD 5,074	13.95
2025-07-17	SELL	-340	18.350	18.440	18.431	USD -6,267	13.90 Loss of -1,540 on sale
2025-07-16	BUY	1,584	17.870	17.990	17.978	USD 28,477	13.88
2025-07-11	SELL	-1,328	17.690	18.045	18.010	USD -23,917	13.80 Loss of -5,589 on sale
2025-07-02	BUY	9,130	16.750	16.760	16.759	USD 153,010	13.71
2025-06-25	BUY	332	17.260	17.540	17.512	USD 5,814	13.59
2025-06-11	BUY	334	14.340	14.800	14.754	USD 4,928	13.45
2025-06-10	BUY	334	14.690	14.780	14.771	USD 4,934	13.44
2025-06-04	SELL	-167	13.820	14.700	14.612	USD -2,440	13.42 Loss of -199 on sale
2025-04-23	BUY	166	14.380	15.440	15.334	USD 2,545	13.22
2025-04-10	SELL	-1,328	13.240	13.663	13.621	USD -18,088	13.09 Loss of -710 on sale
2025-04-08	SELL	-166	12.330	13.420	13.311	USD -2,210	13.09 Loss of -36 on sale
2025-04-07	SELL	-166	12.830	13.785	13.689	USD -2,272	13.10 Loss of -99 on sale
2025-04-04	SELL	-835	12.800	13.730	13.637	USD -11,387	13.10 Loss of -450 on sale
2025-04-01	BUY	2,480	12.530	12.850	12.818	USD 31,789	13.11
2025-03-31	SELL	-483	12.580	12.770	12.751	USD -6,159	13.11 Profit of 175 on sale
2025-03-21	BUY	2,109	12.360	14.250	14.061	USD 29,655	13.15
2025-03-14	SELL	-2,480	11.870	12.255	12.217	USD -30,297	13.22 Profit of 2,478 on sale
2025-03-07	SELL	-310	10.850	11.160	11.129	USD -3,450	13.35 Profit of 687 on sale
2025-03-04	SELL	-155	10.510	10.720	10.699	USD -1,658	13.47 Profit of 430 on sale
2025-02-25	BUY	310	10.560	10.980	10.938	USD 3,391	13.74
2025-02-19	SELL	-154	12.000	12.020	12.018	USD -1,851	13.91 Profit of 291 on sale
2025-02-13	BUY	462	11.920	12.010	12.001	USD 5,544	14.07
2025-02-12	BUY	154	11.630	11.770	11.756	USD 1,810	14.12
2025-02-11	BUY	616	11.550	12.030	11.982	USD 7,381	14.17
2024-12-30	SELL	-4,737	10.620	10.690	10.683	USD -50,605	14.73 Profit of 19,151 on sale
2024-11-18	SELL	-2,490	13.780	14.370	14.311	USD -35,634	15.64 Profit of 3,298 on sale
2024-11-08	SELL	-166	17.040	17.070	17.067	USD -2,833	15.47 Loss of -266 on sale
2024-10-21	SELL	-166	16.720	16.750	16.747	USD -2,780	0.00 Loss of -2,780 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SPRY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	1,036,811	2,339	1,919,450	54.0%
2025-09-18	517,150	2,816	987,030	52.4%
2025-09-17	379,115	0	772,889	49.1%
2025-09-16	623,491	3,700	1,009,540	61.8%
2025-09-15	663,271	2,900	1,595,652	41.6%
2025-09-12	577,300	0	1,228,781	47.0%
2025-09-11	685,503	145,273	1,124,464	61.0%
2025-09-10	556,371	0	984,013	56.5%
2025-09-09	453,162	0	963,620	47.0%
2025-09-08	859,020	224,358	2,428,498	35.4%
2025-09-05	832,450	76,200	2,588,108	32.2%
2025-09-04	957,847	22,360	2,125,953	45.1%
2025-09-03	766,348	0	2,155,073	35.6%
2025-09-02	861,442	11,887	2,040,774	42.2%
2025-08-29	1,336,171	183,205	3,462,653	38.6%
2025-08-28	547,909	1,125	1,082,195	50.6%
2025-08-27	412,301	500	704,469	58.5%
2025-08-26	553,146	2,580	775,647	71.3%
2025-08-25	615,803	0	1,289,829	47.7%
2025-08-22	1,207,260	601	1,546,063	78.1%
2025-08-21	468,222	50,536	608,426	77.0%
2025-08-20	671,679	26,441	1,106,645	60.7%
2025-08-19	623,980	8,735	1,160,286	53.8%
2025-08-18	382,356	1,900	673,955	56.7%
2025-08-15	844,074	725	1,153,241	73.2%
2025-08-14	1,133,778	22,500	1,427,337	79.4%
2025-08-13	1,127,522	39,066	1,770,071	63.7%
2025-08-12	787,913	0	995,285	79.2%
2025-08-11	351,430	640	901,141	39.0%
2025-08-08	132,685	0	238,497	55.6%
2025-08-07	164,593	9,579	265,414	62.0%
2025-08-06	240,878	103	378,523	63.6%
2025-08-05	192,066	0	313,299	61.3%
2025-08-04	293,472	9,962	499,573	58.7%
2025-08-01	429,256	0	556,082	77.2%
2025-07-31	291,624	0	421,552	69.2%
2025-07-30	232,315	0	483,325	48.1%
2025-07-29	172,573	430	276,477	62.4%
2025-07-28	529,668	0	1,110,316	47.7%
2025-07-25	643,378	0	1,004,276	64.1%
2025-07-24	275,442	0	656,207	42.0%
2025-07-23	235,466	0	569,671	41.3%
2025-07-22	197,912	0	274,374	72.1%
2025-07-21	184,000	0	266,530	69.0%
2025-07-18	349,976	0	556,771	62.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE